Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $53.18 in the last session, down -3.22% from day before closing price of $54.95. In other words, the price has decreased by -$3.22 from its previous closing price. On the day, 1.22 million shares were traded. CRNX stock price reached its highest trading level at $55.27 during the session, while it also had its lowest trading level at $52.94.
Ratios:
We take a closer look at CRNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On July 10, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.Stifel initiated its Buy rating on March 25, 2025, with a $60 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when Kalofonos Isabel sold 2,500 shares for $55.00 per share. The transaction valued at 137,500 led to the insider holds 834 shares of the business.
ISABEL KALOFONOS bought 2,500 shares of CRNX for $116,825 on Jan 05 ’26. On Jan 02 ’26, another insider, DANA PIZZUTI, who serves as the Officer of the company, bought 5,000 shares for $46.55 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 5451579904 and an Enterprise Value of 4003201024. For the stock, the TTM Price-to-Sale (P/S) ratio is 3563.12 while its Price-to-Book (P/B) ratio in mrq is 4.69. Its current Enterprise Value per Revenue stands at 2607.949 whereas that against EBITDA is -8.443.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.19, which has changed by 0.39178228 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $57.99, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is 10.28%, while the 200-Day Moving Average is calculated to be 42.51%.
Shares Statistics:
According to the various share statistics, CRNX traded on average about 1.40M shares per day over the past 3-months and 1141100 shares per day over the past 10 days. A total of 102.51M shares are outstanding, with a floating share count of 95.19M. Insiders hold about 7.14% of the company’s shares, while institutions hold 102.19% stake in the company. Shares short for CRNX as of 1767139200 were 13334004 with a Short Ratio of 9.55, compared to 1764288000 on 13873038. Therefore, it implies a Short% of Shares Outstanding of 13334004 and a Short% of Float of 15.97.
Earnings Estimates
. The current assessment of Crinetics Pharmaceuticals Inc (CRNX) involves the perspectives of 10.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.24 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$4.94 and -$5.17 for the fiscal current year, implying an average EPS of -$5.04. EPS for the following year is -$5.18, with 11.0 analysts recommending between -$3.89 and -$6.97.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $7.5M. There is a high estimate of $11.1M for the next quarter, whereas the lowest estimate is $4.6M.
A total of 13 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.54M, while the lowest revenue estimate was $3.7M, resulting in an average revenue estimate of $5.95M. In the same quarter a year ago, actual revenue was $1.04MBased on 13 analysts’ estimates, the company’s revenue will be $60.23M in the next fiscal year. The high estimate is $112.54M and the low estimate is $20.68M.
